Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes.

Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Metabolism. 2014 Oct;63(10):1287-95. doi: 10.1016/j.metabol.2014.07.001. Epub 2014 Jul 9.

PMID:
25088746
2.

High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.

Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G; DCCT/EDIC Research Group.

Nephrol Dial Transplant. 2012 Apr;27(4):1416-23. doi: 10.1093/ndt/gfr454. Epub 2011 Aug 19.

4.

Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients.

Overgaard AJ, McGuire JN, Hovind P, Parving HH, Rossing P, Pociot F.

J Diabetes Complications. 2013 Jan-Feb;27(1):59-63. doi: 10.1016/j.jdiacomp.2012.06.016. Epub 2012 Aug 11.

PMID:
22885250
5.

Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.

Saraheimo M, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, Heikkilä O, Hietala K, Gordin D, Frystyk J, Flyvbjerg A, Groop PH; FinnDiane Study Group.

Diabetes Care. 2008 Jun;31(6):1165-9. doi: 10.2337/dc07-2306. Epub 2008 Mar 17.

PMID:
18346990
6.

Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects.

Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group.

Diabetes Care. 2013 Aug;36(8):2317-23. doi: 10.2337/dc12-2521. Epub 2013 Mar 20.

7.

Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT).

Kern EF, Erhard P, Sun W, Genuth S, Weiss MF.

Am J Kidney Dis. 2010 May;55(5):824-34. doi: 10.1053/j.ajkd.2009.11.009.

10.

Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study.

Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N.

Diabetologia. 2004 Jun;47(6):1020-8. Epub 2004 May 29.

PMID:
15170497
11.

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.

Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, Zinman B, Lachin J; Epidemiology of Diabetes Interventions and Complications Study Group.

Diabetes Care. 2010 Jul;33(7):1536-43. doi: 10.2337/dc09-1098. Epub 2010 Apr 22.

12.
13.

The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes.

Olsen BS, Sjølie AK, Hougaard P, Johannesen J, Marinelli K, Jacobsen BB, Mortensen HB; Danish Study Group of Diabetes in Childhood.

J Diabetes Complications. 2004 May-Jun;18(3):160-4.

PMID:
15145327
15.
16.
17.

Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

J Pediatr. 2001 Dec;139(6):804-12.

PMID:
11743505
18.
19.

Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.

Theilade S, Lyngbaek S, Hansen TW, Eugen-Olsen J, Fenger M, Rossing P, Jeppesen JL.

J Intern Med. 2015 Mar;277(3):362-71. doi: 10.1111/joim.12269. Epub 2014 Jun 23.

20.

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

JAMA. 2003 Oct 22;290(16):2159-67.

Supplemental Content

Support Center